Integer Holdings Corp
NYSE:ITGR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
96.6
141.16
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Integer Holdings Corp
Research & Development
Integer Holdings Corp
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Integer Holdings Corp
NYSE:ITGR
|
Research & Development
-$71.6m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-3%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Research & Development
-$1.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-8%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Research & Development
-$1.5B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-6%
|
|
|
Stryker Corp
NYSE:SYK
|
Research & Development
-$1.4B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Research & Development
-$2.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Research & Development
-$1.1B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-20%
|
|
Integer Holdings Corp
Glance View
Integer Holdings Corporation, a prominent player in the medical device industry, has carved a significant niche by aligning innovation with robust manufacturing capabilities. Founded as a collaborative effort between technical ingenuity and healthcare innovation, Integer primarily engages in the design and production of medical devices and components that are instrumental for the med-tech sector. It serves a diverse clientele that ranges from large healthcare conglomerates to emerging med-tech companies. The company operates through two main segments: Medical and Non-Medical. In the Medical division, Integer excels by providing critical components used in cardiac rhythm management, neuromodulation, and vascular access. It thrives on the premise that precision in manufacturing and innovation are key to producing reliable and effective medical solutions, ensuring that they meet stringent regulatory standards. What truly propels Integer’s financial engine is its commitment to operational excellence and strategic partnerships. By integrating vertically across its production processes, Integer achieves cost efficiencies that allow it to offer competitive pricing without sacrificing quality. Moreover, the company extends its influence through strategic partnerships with prominent healthcare providers, thereby securing long-term contracts and steady revenue streams. This model is supplemented by its Non-Medical segment, where Integer provides high-reliability components for energy, military, and environmental applications. These ventures not only diversify its revenue portfolio but also bolster its resilience against market volatility. Integer’s growth narrative is underscored by a relentless focus on research and development, which facilitates continuous product enhancement and keeps it at the forefront of technological advancement in the medical device industry. Through these strategies, Integer Holdings Corporation not only sustains its market position but also expands its role as a critical enabler in the global healthcare landscape.
See Also
What is Integer Holdings Corp's Research & Development?
Research & Development
-71.6m
USD
Based on the financial report for Sep 27, 2024, Integer Holdings Corp's Research & Development amounts to -71.6m USD.
What is Integer Holdings Corp's Research & Development growth rate?
Research & Development CAGR 10Y
-3%
Over the last year, the Research & Development growth was -13%. The average annual Research & Development growth rates for Integer Holdings Corp have been -13% over the past three years , -10% over the past five years , and -3% over the past ten years .
You don't have any saved screeners yet
